Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.
You may also be interested in...
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
Can The Medicines Company Rebound From A Phase III Blow?
The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011